Brief: Sensei Biotherapeutics To Present Preclinical Data For SNS-101
21/09/2022 22:10
Sept 21 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS TO PRESENT PRECLINICAL DATA FOR
SNS-101,
A CONDITIONALLY ACTIVE VISTA-BLOCKING ANTIBODY, AT THE SIXTH
ANNUAL CRI-ENCI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY
CONFERENCE: TRANSLATING SCIENCE INTO SURVIVAL
Source text for Eikon: ID:nGNX83g25K
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)